- $11.33bn
- $13.32bn
- $2.76bn
- 94
- 31
- 71
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.41 | ||
| PEG Ratio (f) | 0.59 | ||
| EPS Growth (f) | 45.39% | ||
| Dividend Yield (f) | 0.29% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.48 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 20.92 | ||
| Price to Sales | 4.11 | ||
| EV to EBITDA | 17.19 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.95% | ||
| Return on Equity | 3.69% | ||
| Operating Margin | 12.59% | ||
Financial Summary
| Year End 29th Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3,782.74 | 3,827.81 | 3,311.82 | 2,750.57 | 2,755.03 | 2,831.13 | 3,000.74 | -0.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +149.6 | +20.6 | -47.06 | -48.15 | +27.5 | +73.43 | +11.55 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Revvity, Inc. is a provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. The Company has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.
Directors
- Alexandros Michas NEC (63)
- Prahlad Singh PRE (56)
- James Mock CFO (44)
- Joel Goldberg SVP (52)
- Daniel Tereau SVP (54)
- Miriame Victor SVP (40)
- Tajinder Vohra SVP (56)
- Andrew Okun CAO (51)
- Peter Barrett IND (68)
- Samuel Chapin IND (64)
- Sylvie Gregoire IND (60)
- Michel Vounatsos IND (59)
- Frank Witney IND (67)
- Pascale Witz IND (54)
- Last Annual
- December 29th, 2024
- Last Interim
- December 29th, 2024
- Incorporated
- November 13th, 1947
- Public Since
- July 6th, 1965
- No. of Shareholders
- 2,753
- No. of Employees
- 11,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 120,147,286
- Address
- 77 4Th Avenue, WALTHAM, 02451
- Web
- https://www.revvity.com/
- Phone
- +1 7816636900
- Auditors
- Deloitte & Touche LLP
Upcoming Events for RVTY
Dividend For RVTY.N - 0.0700 USD
Q2 2025 Revvity Inc Earnings Release
Similar to RVTY
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
What is the Revvity share price?
As of Today at 22:56 UTC, shares in Revvity are trading at $94.29. This share price information is delayed by 15 minutes.
How has the Revvity share price performed this year?
Shares in Revvity last closed at $94.29 and the price had moved by -7.64% over the past 365 days. In terms of relative price strength the Revvity share price has underperformed the S&P500 Index by -14.75% over the past year.
What are the analyst and broker recommendations for Revvity?
The overall consensus recommendation for Revvity is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Revvity dividend yield?
The Revvity dividend yield is 0.37% based on the trailing twelve month period.
Does Revvity pay a dividend?
Last year, Revvity paid a total dividend of $0.35, and it currently has a trailing dividend yield of 0.37%.Looking ahead, shares in Revvity are due to go ex-dividend on 2025-07-18 and the next dividend pay date is 2025-05-09.
When does Revvity next pay dividends?
Revvity are due to go ex-dividend on 2025-07-18 and the next dividend pay date is 2025-05-09. The historic dividend yield on Revvity shares is currently 0.37%.
How do I buy Revvity shares?
To buy shares in Revvity you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Revvity?
As of the previous close price of $94.29, shares in Revvity had a market capitalisation of $11.33bn.
Where are Revvity shares listed?
Here are the trading details for Revvity:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: RVTY
What kind of share is Revvity?
Based on an overall assessment of its quality, value and momentum Revvity is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Revvity share price forecast for 2025?
The analyst consensus target price for shares in Revvity is $132.82. That is 40.86% above the last closing price of $94.29.
Analysts covering Revvity currently have a consensus Earnings Per Share (EPS) forecast of $4.94 for the next financial year.
Find out moreWhat is the trend in the Revvity share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Revvity. Over the past six months, its share price has underperformed the S&P500 Index by -14.57%.
As of the last closing price of $94.29, shares in Revvity were trading -18.28% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Revvity PE Ratio?
The Revvity PE ratio based on its reported earnings over the past 12 months is 18.41. The shares last closed at $94.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Revvity?
Revvity's management team is headed by:
- Alexandros Michas - NEC
- Prahlad Singh - PRE
- James Mock - CFO
- Joel Goldberg - SVP
- Daniel Tereau - SVP
- Miriame Victor - SVP
- Tajinder Vohra - SVP
- Andrew Okun - CAO
- Peter Barrett - IND
- Samuel Chapin - IND
- Sylvie Gregoire - IND
- Michel Vounatsos - IND
- Frank Witney - IND
- Pascale Witz - IND